By Sam Rory
MYQORZO’s launch in January 2026 gave Cytokinetics its first revenue from a commercial product. The cardiac myosin inhibitor’s December 2025 approval converted the South San Francisco biotech from a clinical-stage company into one managing the particular complexity of building a commercial business from scratch while tracking two major milestones in the same calendar year: a European market entry and a Phase 3 readout in non-obstructive hypertrophic cardiomyopathy.
Institutional investors with reported positions in Cytokinetics at the start of the launch period include BlackRock, Fidelity, Vanguard, T. Rowe Price, Deep Track Capital, and Armistice Capital, a group spanning passive index allocations and active healthcare specialists.
Launch Mechanics and the Access Ramp
MYQORZO treats adults with symptomatic obstructive hypertrophic cardiomyopathy, a condition in which abnormal cardiac muscle thickening impairs blood flow out of the heart. The FDA approval came with a Risk Evaluation and Mitigation Strategy requiring echocardiographic monitoring before and during treatment, a protocol that shapes which cardiologists engage early and how quickly new patient starts can be processed.
Cytokinetics concentrated its initial commercial effort on roughly 750 high-volume cardiologists who account for approximately 80 percent of existing cardiac myosin inhibitor prescriptions, while deploying more than 125 field sales colleagues across a broader network reaching approximately 11,000 cardiologists nationally. Within weeks of launch, more than 700 cardiologists had completed REMS enrollment and training.
A patient bridge program provides up to 12 months of free drug for commercially insured patients without active coverage and up to two months for Medicare patients awaiting formulary decisions. Payer coverage decisions for specialty drugs entering established categories typically lag launches by several quarters, and Cytokinetics projected commercial insurance access comparable to Bristol Myers Squibb’s Camzyos by the fourth quarter of 2026. The company entered the year with approximately $1.2 billion in cash, providing a financial cushion through the coverage-building period.
At the 25th Annual Needham Virtual Healthcare Conference in April 2026, Cytokinetics management described early prescribing activity among REMS-enrolled physicians as encouraging, with positive reimbursement outcomes for commercially insured patients.
Competing With Camzyos
Camzyos, the first approved cardiac myosin inhibitor, generated more than $1 billion in combined U.S. and European sales in 2025 after three years on the market. Both drugs target cardiac myosin; the competitive difference between them centers on REMS protocol complexity.
Camzyos requires drug-drug interaction monitoring and mandates dose interruption in certain scenarios, administrative steps that have created friction for prescribers and pharmacies managing the category. MYQORZO’s label allows dose adjustment rather than full interruption in most situations and does not require drug-interaction monitoring. RBC Capital Markets described those differences as likely to “materially lower barriers to prescribing” for MYQORZO. Cytokinetics set a commercial target of more than 50 percent new-to-brand prescription share among patients entering the cardiac myosin inhibitor class in 2026.
More than 80 percent of the eligible obstructive HCM population in the United States remains untreated with either drug, a patient base that both companies are only beginning to reach.
Germany and the European Rollout
The European Commission granted marketing authorization for MYQORZO in early 2026 following a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use. Cytokinetics targeted Germany for a second-quarter 2026 launch under the AMNOG pricing framework, with additional Western European markets planned for later in 2026 and a broader regional rollout into 2027.
ACACIA-HCM and the Non-Obstructive Population
The most closely watched clinical event on Cytokinetics’ calendar is the Phase 3 ACACIA-HCM trial, testing aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy. Non-obstructive disease, which accounts for roughly half the diagnosed and symptomatic HCM population in the United States, has no approved treatment. Camzyos failed in Phase 3 for this indication, leaving the field open.
Data from ACACIA-HCM is expected in the second quarter of 2026. A positive result would leave Cytokinetics as the only company with approved therapies for both obstructive and non-obstructive HCM, roughly doubling the addressable patient population in the United States beyond what MYQORZO currently reaches.
Cytokinetics is no longer positioning for a regulatory milestone. The company is managing the more complicated work of building a commercial business: formulary negotiations, prescriber education, payer timing, and European market entry, all while carrying a Phase 3 readout that could reshape how large the overall opportunity becomes.
